A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

May 31, 2017

Study Completion Date

September 30, 2017

Conditions

Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

Interventions

DRUG

145 mg/m2 NKTR 102

DRUG

120 mg/m2 NKTR 102

DRUG

50 mg/m2 NKTR 102

Trial Locations (3)

University Hospitals Case-Medical Center Seidman Cancer Center, Cleveland

USC/LA County, Los Angeles

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco